Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX-826 in Chinese female patients with androgenetic alopecia
NCT06409650Phase 2Completed
- Sponsor
- Suzhou Koshine Biomedica
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrilutamide in androgenetic alopecia (AGA), sponsored by Suzhou Koshine Biomedica. Started Nov 2021; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06409650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409650.